Pediatric Drug Development and Pharmacometrics: Key Questions Sponsors Must Answer
Download Certara’s expert guide on pharmacometrics and pediatric drug development. Learn how modeling, MIDD, and…
CertaraMarch 19, 2026
Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026
Explore how model-informed drug development and AI are advancing pharmacoequity and shaping the future of…
CertaraMarch 11, 2026
Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer
This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…
Danielle PillsburyMarch 4, 2026
ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success
Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…
CertaraMarch 3, 2026
Embracing Model-Informed Drug Discovery: The Path to Better Clinical Outcomes
We cover the evidence of biosimulation improving clinical success rates, making the case for model-informed…
CertaraFebruary 27, 2026
On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…
CertaraFebruary 26, 2026
